[SCHEDULE 13G/A] scPharmaceuticals Inc. SEC Filing

Rhea-AI Filing Summary

Luther King Capital Management Corp. (LKCM) and its founder, J. Luther King, Jr., have filed Amendment No. 6 to Schedule 13G for scPharmaceuticals Inc. (SCPH) dated 30 Jun 2025. The filing discloses continued beneficial ownership above the 5 % threshold:

• LKCM reports 3,541,170 common shares with sole voting and dispositive power, representing 6.7 % of SCPH’s outstanding stock.
• J. Luther King, Jr. individually reports 3,669,170 common shares (sole voting/dispositive power) for a 7.0 % stake.

The amendment confirms that the shares are held in the ordinary course of business and not for the purpose of influencing control of the issuer. Both reporting persons classify as an “Investment Adviser” (LKCM) and “Individual” (King) under Rule 13d-1(b). No joint filing or group status is claimed, and there are no shared voting or dispositive powers.

Implications for investors: 1) LKCM remains one of SCPH’s larger institutional holders, potentially signaling confidence in the company’s prospects. 2) Because the ownership level is stable at ~7 %, the amendment itself does not suggest an imminent change in strategic direction or control. 3) Any future movement above or below the 5 % threshold would trigger additional filings, providing transparency on LKCM’s trading activity.

Positive

• Significant passive stake maintained: LKCM and its founder still control roughly 7 % of SCPH, indicating continued institutional confidence.

Negative

• Potential overhang risk: A 7 % holder could create selling pressure if LKCM decides to exit, though no such intent is stated.

Insights

Buy-Side Portfolio Manager

TL;DR: LKCM re-affirms ≈7 % SCPH stake; neutral impact, signals ongoing institutional support without control intent.

LKCM’s 3.5 M-share position (6.7 %) and King’s 3.7 M (7.0 %) confirm a meaningful, yet passive, ownership block. The absence of shared voting rights and the certification of non-control intent suggest LKCM remains a traditional, long-only holder rather than an activist. For existing shareholders, this provides a modest vote of confidence and liquidity support but does not alter SCPH’s strategic trajectory. The filing is routine—an amendment required as positions or share counts change modestly—so market impact should be limited.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 6)

scPharmaceuticals Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

810648105

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 810648105

1

Names of Reporting Persons

Luther King Capital Management Corporation

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,541,170.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,541,170.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,541,170.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.7 %

12

Type of Reporting Person (See Instructions)

IA, CO

SCHEDULE 13G

CUSIP No. 810648105

1

Names of Reporting Persons

J. Luther King, Jr.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,669,170.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,669,170.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,669,170.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.0 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: scPharmaceuticals Inc.
(b)	Address of issuer's principal executive offices: 25 Mall Road, Suite 203, Burlington, Massachusetts 01803
Item 2.
(a)	Name of person filing: Luther King Capital Management Corporation J. Luther King, Jr.
(b)	Address or principal business office or, if none, residence: 301 Commerce Street, Suite 1600, Fort Worth, Texas 76102
(c)	Citizenship: Luther King Capital Management Corporation - Delaware / J. Luther King, Jr. - USA
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 810648105
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Luther King Capital Management Corporation - 3,541,170 J. Luther King, Jr. - 3,669,170
(b)	Percent of class: Luther King Capital Management Corporation - 6.7% J. Luther King, Jr. - 7.0
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Luther King Capital Management Corporation - 3,541,170 J. Luther King, Jr. - 3,669,170
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: Luther King Capital Management Corporation - 3,541,170 J. Luther King, Jr. - 3,669,170
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Luther King Capital Management Corporation

Signature:	/s/ J. Luther King, Jr.
Name/Title:	J. Luther King, Jr., President
Date:	07/21/2025

J. Luther King, Jr.

Signature:	/s/ J. Luther King, Jr.
Name/Title:	J. Luther King, Jr.
Date:	07/21/2025

FAQ

Why did LKCM file an Amendment 6 Schedule 13G for SCPH?

To update its passive ownership disclosure, confirming a 6.7 % stake as of 30 Jun 2025.

How many scPharmaceuticals shares does J. Luther King, Jr. own?

He reports 3,669,170 common shares, representing 7.0 % of SCPH.

Is LKCM seeking control of scPharmaceuticals?

No. The certification states the shares are held in the ordinary course and not to influence control.

What triggers future 13G/13D filings for SCPH?

Any ownership change that moves LKCM above or below key thresholds (5 %, or 1 % increments thereafter) requires an updated filing.

Does the filing indicate a change in SCPH’s strategy or governance?

The filing is passive; it does not signal any strategic or governance changes at SCPH.